TRIAL HIV VACCINE TRIGGERS ELUSIVE AND ESSENTIAL ANTIBODIES, POINTING THE WAY TOWARD A SUCCESSFUL VACCINE

Summary from the TLDR newsletter

The Duke Human Vaccine Institute has developed an HIV vaccine candidate that triggers low levels of a type of broadly neutralizing HIV antibodies within weeks. It targets an area of the HIV-1 outer envelope that remains stable even as the virus mutates. Antibodies against this region can block infection by many different circulating strains of HIV. More work still needs to be done to create a more robust response - a successful HIV vaccine will likely have at least three components all aimed at distinct regions of the virus.